Treatment With Avacopan in ANCA–Associated Vasculitis With Kidney Involvement
Duvuru Geetha, Frank B. Cortazar, Annette Bruchfeld, Andreas Kronbichler et autres
9 citationsKidney International Reports
István Szombati
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
20Publications signalées
1351Citations signalées
0Affiliations récentes
Domaines associés
Vasculitis and related conditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaRheumatoid Arthritis Research and TherapiesOtitis Media and Relapsing PolychondritisLymphoma Diagnosis and Treatment
Publications récentes
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
Vibeke Strand, David Jayne, Audra Horomanski, Huibin Yue et autres
31 citationsThe Lancet Rheumatology
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
Frank B. Cortazar, John L. Niles, David Jayne, Peter A. Merkel et autres
92 citationsKidney International Reports
SAT0200 Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study
René Westhovens, Rieke Alten, Kevin Winthrop, Maria Greenwald et autres
1 citationAnnals of the Rheumatic Diseases
THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks
Rieke Alten, René Westhovens, Arthur Kavanaugh, Mark C. Genovese et autres
4 citationsAnnals of the Rheumatic Diseases
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier et autres
607 citationsJournal of the American Society of Nephrology
MO039SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR)
David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier et autres
3 citationsNephrology Dialysis Transplantation
OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity
Josef S Smolen, Serghei Popa, István Szombati, Daniel J. Wallace et autres
2 citationsAnnals of the Rheumatic Diseases
OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in Anca-Associated Renal Vasculitis
David Jayne, Annette Bruchfeld, Matthias Schaier, Kazimierz Ciechanowski et autres
13 citationsAnnals of the Rheumatic Diseases
Efficacy of Oral C5aR Inhibitor CCX168 on Non-Renal Disease Activity in Patients withAntineutrophil Cytoplasmic Antibody-Associated Vasculitis
David Jayne, Annette Bruchfeld, Matthias Schaier, Michel Jadoul et autres
0 citationsDigital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B))
Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis
David Jayne, Annette Bruchfeld, Matthias Schaier, Kazimierz Ciechanowski et autres
4 citationsDigital Access to Libraries
C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168
Annette Bruchfeld, Matthias Schaier, Michel Jadoul, Daina Selga et autres
3 citationsLa Presse Médicale
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.